92 results about "Bolus injection" patented technology

The invention is directed to an implantable pump. The implantable pump has a port with light emitters indicating the location of the port. The port can be useful in providing bolus injections or the refilling of reservoirs. The light emitters can be arranged in various forms about the port including linear, triangular, square, or circular, among others. If more than one port is located on a device, these ports can be differentiated by differing colors and arrangements of emitters. In addition, various circuitries can be used to activate the emitters. These circuitries can include a coil and capacitor arrangement that provide a separate power source from that of the pump.

A device for control of fluid flow with closed loop quasi static adjustment of in-line pressure-based resistance. The disclosed device and methods of using the device provide for the ability to control a flow rate with a highly portable device; the ability for an operator to safely use the device with minimal training; the ability to automatically switch between a primary and secondary fluid; the ability to maintain a flow rate through a tubing set even when the control device is removed; and the ability to measure fluids introduced with a manual bolus injection.

The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.

A combined insulin and amylin and / or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and / or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus insulin levels to cover the meal, without producing hypoglycemia after the meal. This can be combined with an adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of the insulin and amylin and / or GLP-1 mimetic combination. A GLP-1 mimetic may be combined with either rapid acting or basal insulin formulations. As a result, a patient using the combination formulation therapy may only need to inject half as many times per day.

A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day. Experiments have been performed to demonstrate, the importance of the addition of specific acids to hexameric insulin to enhance speed and amount of absorption and preserve bioactivity following dissociation into the monomeric form by addition of a chelator such as EDTA. As shown by the examples, the preferred acids are aspartic, maleic, succinic, glutamic and citric acid. These are added in addition to a chelator, preferably ethylenediaminetetraacetic acid (EDTA). The results show that the citric acid formulation was more effective at dropping the blood glucose rapidly than the identical rapid acting formulation prepared with HCl in swine. Charge masking by the polyacid appears to be responsible for rapid insulin absorption. EDTA was not effective when used with adipic acid, oxalic acid or HCl at hastening the absorption of insulin. These results confirm the results seen in clinical subjects and patients with diabetes treated with the rapid acting insulin in combination with citric acid and EDTA.

The invention relates to an actuation system and method for an implantable infusion pump. In an example, a working fluid is placed in an actuator. Upon actuation, the working fluid is driven into a piston cylinder. Upon deactuation, the actuator draws the fluid from the cylinder through a restrictor at a rate dictated by the motivating force, fluid viscosity, and restriction. Driving of the piston may produce a bolus dosage or fill a supplemental flow chamber for subsequent delivery. The exemplary system may be configured by selecting a fluid volume and a viscosity. These, in combination, produce a prescribed fluid delivery rate (or recharge rate) and cumulative flow volume provided to a patient over a time period or in a bolus dose. The system may also be configured to limit the total dosage of a bolus injection, or the rate of a supplemental dosage. In this manner, the system is safe, preventing overdose.

A device for control of fluid flow with closed loop quasi static adjustment of in-line pressure-based resistance. The disclosed device and methods of using the device provide for the ability to control a flow rate with a highly portable device; the ability for an operator to safely use the device with minimal training; the ability to automatically switch between a primary and secondary fluid; the ability to maintain a flow rate through a tubing set even when the control device is removed; and the ability to measure fluids introduced with a manual bolus injection.

An infusion pump includes a plurality of projections configured so that they enter the subcutaneous region of the patients skin and provides a painless means of creating a breach in the stratum corneum which is sealed against leakage by the skin surrounding each projection and provides a flow path for either a basal and bolus injection of medication. The pump includes a drug reservoir containing a drug. The pump includes a microactuator and includes a housing having a foundation or lid which opens and closes so that the medication container can be inserted and supported in a delivery mode position. A micro actuator is used to advance either a roller or a piston in communication with the medication container. Attached to the micro-actuator is a device that is mounted for movement along the access of the medication container. The device indexes along the medication container that is used to dispense the medication.

The Breviscapine infusion preparation is compounded with Breviscapine as main component, glucose or sodium chloride, propylene glycol, L-arginine, sodium bisulphate, EDTA-2Na and water for injection through certain technological process. The preparation is suitable for great dosage application clinically to avoid cross infection caused by intermediate links. In addition, the present invention is clear and stable.

A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is decreased so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day. Experiments have been performed to demonstrate the importance of the addition of specific acids to hexameric insulin to enhance speed and amount of absorption and preserve bioactivity following dissociation into the monomeric form by addition of a chelator such as EDTA. As shown by the examples, the preferred acids are aspartic, glutamic and citric acid. These are added in addition to a chelator, preferably ethylenediaminetetraacetic acid (EDTA). The results show that the citric acid formulation was more effective at dropping the blood glucose rapidly than the identical rapid acting formulation prepared with HCl in swine. Charge masking by the polyacid appears to be responsible for rapid insulin absorption. EDTA was not effective when used with adipic acid, oxalic acid or HCl at hastening the absorption of insulin. These results confirm the results seen in clinical subjects and patients with diabetes treated with the rapid acting insulin in combination with citric acid and EDTA.

This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise.

A combined insulin and amylin and / or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and / or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus insulin levels to cover the meal, without producing hypoglycemia after the meal. This can be combined with an adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of the insulin and amylin and / or GLP-1 mimetic combination. A GLP-1 mimetic may be combined with either rapid acting or basal insulin formulations. As a result, a patient using the combination formulation therapy may only need to inject half as many times per day.

The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.

A combined rapid acting-long acting insulin formulation has been developed in which the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.

An injectable formulation containing a rapid acting insulin and a long acting insulin has been developed. The pH of the rapid acting insulin is adjusted so that the long acting insulin, remains soluble when they are mixed together. Preferably, the formulation is administered before breakfast, provides adequate bolus insulin levels to cover the meal and basal insulin for up to 24 hours, and does not produce hypoglycemia after the meal. Lunch and dinner can be covered by two bolus injections of a fast, rapid, or very rapid acting insulin. Alternatively, by adjusting the ratio of rapid to long acting insulin, the long acting insulin may be shortened to a 12 hour formulation, and re-administered to the patient at dinner time, providing a safe and effective basal insulin level until morning. As a result, a patient using intensive insulin therapy should only inject three times a day.

A combined rapid acting-long acting insulin formulation has been developed in which the pH of the rapid acting insulin is decreased so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.

Significant liver growths such as HCC lesions are detected during a contrast agent ultrasound exam by their early reception of contrast and brightening following a bolus injection, as compared with surrounding normal tissue and benign growths. A pixel classifier (30) looks for and identifies pixel or voxel regions where this early wash-in of contrast occurs and denotes these pixel or voxel locations in a parametric image. The pixel classifier analyzes pixel or voxel values from a sequence of images and identifies suspicious regions in an image by uniquely coding the points in a parametric liver image where early wash-in occurs .

Indicator dilution techniques are used to measure vascular access flow rates during routine hemodialysis. A bolus injection port is used to infuse a specific volume (V.sub.i) of an indicator diluent, such as saline or dye, into the patient cardiovascular circuit by one of the following: 1. Needle injection of a known volume (bolus) of indicator diluent directly into the access site in the presence or absence of the hemodialysis circuit. 2. Infusion of an indicator diluent into the arterial, venous line upstream of the venous needle. 3. Turning the ultrafiltration of the dialysis delivery system from OFF to ON and OFF again over a predetermined time period. 4. In a hemodialysis circuit, turning on the hemodialysis pump and using the priming saline volume as a single saline bolus. A transdermal sensor is used to measure the percent change in a blood parameter. The sensor is positioned directly over the vascular access site a prescribed distance downstream of the injection site and upstream of the access-vein connection. The sensor employs emitter and detector elements at multiple spacings (d.sub.1, d.sub.2) for the purpose of measuring the bulk absorptivity (.alpha.) of the area immediately surrounding and including the access site, and the absorptivity (.alpha..sub.0) of the tissue itself.

The invention discloses a blockage pressure detecting processing device for injection pumps, comprising a frame; a lead screw which is connected with the frame via positive or reversed rotation, is provided with a nut and is connected with the bolus injection head of the injection pump via the nut; a pressure sensor fixed on the frame; and a force transmission component fixed on the pressure sensor, whose first end is axially preloaded on the end of the lead screw for transmitting the axial pressure of the lead screw to the pressure sensor. The invention further discloses a blockage pressure detecting processing method for injection pumps, comprising: detecting the blockage pressure of an injection pump; according to the difference between the blockage pressure and a preset value, controlling a step motor, to preload the force transmission component on the end face of the lead screw in the detection and treatment on the blockage pressure of the injection pump, and keeping the force transmission component against the end face of the lead screw. The invention has high stability, can real-timely detect the blockage pressure of injection pump on the bolus injection head, thereby confirming the performance of injection pumps and alarming for dropped injection pump caused by manual factors.

A wearable, self-contained drug infusion device is disclosed that is capable of achieving the precise flow rate control needed for dose-critical drugs such as insulin. In preferred embodiments of the device, at least two flow channels are utilized in conjunction with a series of valves for providing a user with selectable, constant flow rate control. The device can be made with small dimensions so that it can be worn by the user with a minimum of discomfort and inconvenience. In addition, the simple mechanical nature of the device provides the user with close control over the flow rate, which is required for safe and effective delivery of insulin and other drugs. Also, the absence of electronic components allows the device to be manufactured inexpensively. The device is provided with a first channel that is long and narrow, functioning as a flow restrictor. The first channel is preferably provided in a serpentine pattern. A second channel is also provided that has a larger cross section so that flow is not restricted. A series of valves are used to force the flow of fluid through a selectable portion of the serpentine portion of the first channel before entering the remainder of the second channel and flowing to the delivery cannula. In one embodiment of the device, a needle port is provided in fluid communication with the delivery cannula for delivering bolus injections. In another embodiment, a bolus button is provided for delivering bolus injections. A flow restrictor is preferably included in the bolus button to limit the rate at which the bolus button refills.

An injectable formulation containing a combination of a rapid acting insulin and a long acting insulin has been developed wherein the pH of the rapid acting insulin is adjusted so that the long acting insulin, e.g. insulin glargine, remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for up to 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. Alternatively, through adjustment of the ratio of rapid acting insulin to long acting insulin, the long acting insulin may be shortened to a 12 hour formulation. This rapid and long acting blend is re-administered to the patient at dinner time, providing a safe and effective basal insulin level until morning. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.

The invention discloses a Levetiracetam tablet and preparation method thereof. Levetiracetam is a bolus injection medicine with bad compressibility and proportion of supplementary materials which can be added is small. Quality of Levetiracetam is unstable and it is hard to produce Levetiracetam industrially. The invention comprises components of weight percentage content: 70% to 80% of Levetiracetam as active component, 1.5% to 8.0% of plasticizer, 9% to 17% of disintegrant, 3% to 14% of filler, 0.1% to 0.5% of bond and 0.1% to 3% of fluidizer. Addition of plasticizer is added by inner way of wet granulation. Levetiracetam as active component has bad mechanic compressibility. The invention adds plasticizer to solve tablet compression difficulty in industrial embodiment thoroughly, which realizes the purpose of being suitable for coating with stable quality and easy industrial application.

Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

An on-body injector and method of use including an on-body injector for use with an injection device. The on-body injector includes a bolus reservoir; a bolus injection needle in fluid communication with the bolus reservoir, the bolus injection needle having a bolus injection needle tip aligned with the injection port, the bolus injection needle being slideably biased away from the injection port to define a gap between the bolus injection needle tip and the injection port; and a button operably connected to the bolus injection needle to slide the bolus injection needle along the injection axis. The button is operable to advance the bolus injection needle tip to close the gap and advance the bolus injection needle tip into the injection port. The button is further operable to advance a plunger through the bolus reservoir to deliver a predetermined bolus volume to the patient through the injection flow path.

An electronic injector including an electronic on-body injector for use with a patient to deliver a fluid through an injection device. The electronic on-body injector includes a fluid reservoir; a MEMS pump; a bolus injection needle, the bolus injection needle having a bolus injection needle tip aligned with the injection port, the bolus injection needle being slideably biased away from the injection port to define a gap; and a bolus needle button operably connected to the bolus injection needle to slide the bolus injection needle along the injection axis. The bolus needle button is operable to advance the bolus injection needle tip to close the gap and advance the bolus injection needle tip into the injection port to form a bolus injection flow path. The bolus needle button is further operable to activate the MEMS pump to deliver a predetermined bolus volume.

The invention provides a tropisetron hydrochloride freeze-dry preparation for treating emesis, containing tropisetron hydrochloride, gelatin, dextran, oleophilic emulsifier, hydrophilic emulsifier and freeze-dry supporting agent. The invention also relates to a preparation method of the tropisetron hydrochloride freeze-dry preparation, containing the following steps: (1) the tropisetron hydrochloride is added into injection water and completely dissolved; (2) the gelatin and the oleophilic emulsifier are added in solution prepared in step (1) to prepare water-in-oil emulsion; (3) dextran solution and the hydrophilic emulsifier are added in the solution prepared in step (2) to prepare water-in-oil-in-water double emulsion; (4) the prepared double emulsion is dropped by bolus injection into strong base solidified liquor in a high-voltage electrostatic field by an orifice; after solidifying, a microcapsule is filtered and washed by water or PH regulator to lead PH to be 5-7; (5) the freeze-dry supporting agent is dissolved in the injection water and mixed with the microcapsule evenly; after subpackage and freeze drying, the tropisetron hydrochloride freeze-dry preparation is obtained.

The invention discloses a syringe gripper capable of preventing contamination of medicine dispensing. The syringe gripper capable of preventing the contamination of medicine dispensing is matched with an existing disposable syringe and consists of needle cylinder fixing nozzles, a pintle fixing nozzle, a lifting rod, a fixed handle, a free handle, a spring and a gripper body. The pintle of the syringe is locked temporarily by the fixed nozzle of the pintle located at the top of the gripper body, then a syringe needle cylinder bulge and a syringe needle cylinder are respectively locked temporarily by taking advantage of the two needle cylinder fixing nozzles located in the middle of the gripper body, when the free handle is pulled, the pintle of the syringe is lifted by the effect of a lifting rod which is formed by the connection of the fixed nozzle of the pintle and the free handle to achieve the suction of liquid; when the free handle is loosened, the pintle of the syringe is lowered under the action of the spring to complete the bolus injection of the liquid. Fingers of an operator will not touch the pintle during the operation, so that the liquid contamination risk can be effectively prevented during the configuration of the intravenous infusion, the triggered pyrogenic transfusion response and the hidden medical security danger which endangers the life safety of patients are resolved.

An on-body injector and method of use including an on-body injector for use with an injection device. The on-body injector includes a bolus reservoir; a bolus injection needle in fluid communication with the bolus reservoir, the bolus injection needle having a bolus injection needle tip aligned with the injection port, the bolus injection needle being slideably biased away from the injection port to define a gap between the bolus injection needle tip and the injection port; and a button operably connected to the bolus injection needle to slide the bolus injection needle along the injection axis. The button is operable to advance the bolus injection needle tip to close the gap and advance the tip into the injection port. The button is further operable to advance a plunger through the bolus reservoir to deliver a predetermined bolus volume to the patient through the injection flow path.